Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study

Table 4

Glycemic indexes and laboratory assays.

Variable
HbA1c (%)	7.1 ± 1.5
Fasting BGLs (mg/dL)	124 ± 48
Preprocedural values
Creatinine (mg/dL)	0.86 ± 0.28
Creatinine clearance (mL/min/1.73 m^2)	101 ± 34
NGAL (pg/mL)	1.5 ± 1.0
Troponin I (ng/mL)	0.13 ± 0.27
CGM values
Max BGL (mg/dL)	254 ± 62
Min BGL (mg/dL)	63 ± 14
Total average BGL (mg/dL)	126.8 ± 34.6
Total SD BGL (mg/dL)	33 ± 15.8
Glycemic CV (%)	25.9 ± 8.7
MAGE (mg/dL)	80 ± 40
MAGE-up (mg/dL)	80 ± 40
MAGE-down (mg/dL)	60 ± 70
CONGA-1 (mg/dL)	23.7 ± 11.3
CONGA-2 (mg/dL)	33.6 ± 16.4
CONGA-4 (mg/dL)	43.3 ± 20.3

Values are given as mean ± SD or (%). BGL: blood glucose level; CGM: continuous glucose monitoring; CONGA (1, 2, 4): continuous overall net glycemic action (at 1 hour, 2 hours, and 4 hours); CV: coefficient of variability; HbA1c: glycated haemoglobin; MAGE: mean amplitude glycemic excursions; NGAL: neutrophil associated gelatinase lipocalin; PCI: percutaneous coronary intervention; SD: standard deviation.